Antiobesity Medications in Patients With Heart Failure
Sureya F Hussani,
Kelly Nguyen,
Ka Man Yu
и другие.
JACC Heart Failure,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Therapeutic Ketosis for Heart Failure: A State-of-the-Art-Review
Journal of Cardiac Failure,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 1, 2025
Heart
failure
is
characterized
by
an
energy-deprived
heart,
and
in
recent
years
it
has
been
found
that
the
failing
heart
increases
ketone
body
oxidation
to
meet
its
energy
demands.
Accumulating
evidence
suggests
this
metabolic
adaptation
cardioprotective,
suggesting
interventions
boost
blood
levels
could
aid
heart.
Indeed,
multiple
small
clinical
trials
with
short-term
follow
up
have
demonstrated
supplying
exogenous
bodies
may
improve
myocardial
function
across
various
manifestations
of
failure.
As
such,
therapeutic
ketosis,
which
a
state
are
mildly
elevated,
great
potential
ameliorate
Therapeutic
ketosis
can
be
achieved
endogenously
via
exercise
or
dietary
practices,
exogenously
supplementation
bodies,
pharmacologically
treatment
sodium-glucose
cotransporter-2
inhibitor.
Although
ketosis-inducing
practices
cannot
routinely
recommended
patients
at
time
due
lack
robust
data
regarding
long-term
benefits
risks,
anecdotal
some
begun
adopt
so
important
for
clinicians
aware
how
optimally
manage
who
ketosis.
In
review,
we
discuss
metabolism
failure,
current
framework
distinguish
between
pathologic
ketoacidosis,
practical
considerations
managing
adhering
practices.
Язык: Английский
Treatment options for heart failure in individuals with overweight or obesity: a review
Future Cardiology,
Год журнала:
2025,
Номер
unknown, С. 1 - 15
Опубликована: Март 18, 2025
Obesity
and
heart
failure
are
interlaced
global
epidemics,
each
contributing
to
significant
morbidity
mortality.
is
not
only
a
risk-factor
for
failure,
but
also
complicates
its
management,
by
distinctive
pathophysiological
mechanisms
cumulative
comorbidities,
requiring
tailored
treatment
plan.
To
present
current
options
in
individuals
with
overweight/obesity,
emphasizing
available
pharmacological
therapies,
non-pharmacological
strategies,
the
management
of
related
comorbidities.
We
conducted
comprehensive
literature
review
regarding
results
treatments
including
cornerstone
interventions
as
well
emerging
therapeutic
options.
Specific
drug
classes,
angiotensin
receptor-neprilysin
inhibitors,
mineralocorticoid
receptor
antagonists,
sodium-glucose
cotransporter-2
have
demonstrated
consistent
efficacy
irrespective
body
mass
index,
while
diuretics
remain
key
fluid
management.
Glucagon-like
peptide-1
agonists
shown
promising
improving
relevant
outcomes
warrant
further
research.
Non-pharmacological
approaches,
weight-loss
strategies
lifestyle
modifications,
improve
symptoms,
exercise
tolerance
quality
life.
Managing
overweight/obesity
requires
multidisciplinary,
individualized
approach
integrating
Emerging
therapies
preventive
arise
address
unique
challenges
this
population
provide
improved
outcomes.
Язык: Английский
Impact of Lifestyle Modifications Along With Pharmacological Treatment of Heart Failure: A Narrative Review
Elizabeth Caroline Palaparthi,
Priyanka Kanth,
Arockiamary Ignasimuthu
и другие.
Cureus,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 1, 2025
Heart
failure
(HF)
remains
a
leading
cause
of
morbidity
and
mortality
worldwide.
While
pharmacological
therapy
is
foundational,
lifestyle
modifications
are
increasingly
recognised
for
their
complementary
role.
This
narrative
review
explores
the
synergistic
effects
interventions,
combined
with
treatment,
in
HF
management.
A
literature
search
(2000-2025)
was
conducted
using
PubMed,
Scopus,
Cochrane,
Google
Scholar,
to
identify
studies
on
integrative
approaches
care.
Lifestyle
changes,
such
as
dietary
modification,
exercise,
weight
management,
smoking
alcohol
cessation,
psychosocial
support,
enhance
efficacy
standard
therapies,
improve
quality
life,
reduce
hospitalisations.
Integration
medications,
like
renin-angiotensin-aldosterone
system
(RAAS)
inhibitors,
beta-blockers,
sodium-glucose
cotransporter-2
(SGLT2)
shows
improved
neurohormonal
balance,
reduced
inflammation,
better
endothelial
function,
delayed
cardiac
remodelling.
However,
socioeconomic
cultural
barriers
challenge
real-world
implementation.
Combining
interventions
pharmacotherapy
provides
holistic,
patient-centred
strategy
Future
efforts
should
focus
personalised
care,
multidisciplinary
teams,
policy
adherence
outcomes.
Язык: Английский
Obesity and heart failure—the role of GLP-1 receptor agonists
Herz,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 2, 2025
Язык: Английский
Associations of Body Mass Index on worsening of heart failure and mortality in patients with heart failure and reduced left ventricular ejection fraction: A 10-year follow-up study (A NorthStar Substudy)
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2025,
Номер
unknown
Опубликована: Май 6, 2025
Background
Obesity
is
common
in
heart
failure
with
reduced
ejection
fraction
(HFrEF).
As
anti-obesity
treatments
advance,
understanding
how
body
mass
index
(BMI)
affects
outcomes
HFrEF
increasingly
important.
Objective
To
examine
whether
a
BMI
>27
kg/m²
linked
to
higher
risks
of
all-cause
mortality,
cardiovascular
death,
and
(HF)
hospitalization
patients.
Methods
This
study
included
1,017
clinically
stable,
medically
optimized
patients
from
the
NorthStar
(2005–2009),
followed
through
2023
using
Danish
registries.
Outcomes
were
assessed
Cox
models
adjusted
for
prognostic
factors.
The
primary
endpoint
was
mortality;
secondary
endpoints
HF
hospitalization,
composite
mortality
or
hospitalization.
Subgroup
analyses
compared
categories
(<24,
24–27,
kg/m²).
Results
Patients
had
more
diabetes
(27.8%
vs.
17.7%)
lower
NT-proBNP
(median
776
1,163
pg/mL)
than
those
similar
etiology.
Over
median
8.8
years,
821
(80.7%)
died,
including
444
deaths,
740
(72.8%)
hospitalized
HF.
A
35
27
associated
non-significant
increased
(HR
1.18,
95%
CI
0.94–1.48)
but
significantly
1.42,
1.05–1.92),
1.33,
1.05–1.67),
outcome
1.30,
1.06–1.60).
analysis
showed
24–27
ischemic
cardiomyopathy
1.31,
1.05–1.64),
not
non-ischemic
0.86,
0.66–1.12),
interaction
p=0.015.
Conclusion
Among
patients—especially
cardiomyopathy—BMI
worse
outcomes,
challenging
“obesity-survival
paradox”
highlighting
importance
effective
weight
management.
Язык: Английский
Role of Bariatric Surgery in Patients with Advanced Heart Failure
Surgery for Obesity and Related Diseases,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 1, 2025
Язык: Английский
Emerging Role of Weight-Loss Medications in the Management of Heart Failure: Current Evidence and Future Perspectives
American Journal of Cardiovascular Drugs,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 28, 2025
Язык: Английский
Bariatric surgery in patients with obesity and end-stage heart failure with left ventricular assist devices: a brief guide
Metabolism and Target Organ Damage,
Год журнала:
2024,
Номер
4(4)
Опубликована: Окт. 6, 2024
The
prevalence
of
obesity
is
increasing
worldwide,
leading
to
a
rise
in
several
comorbidities,
and
itself
an
important
risk
factor
for
heart
failure.
Patients
with
end-stage
failure
are
often
not
eligible
transplantation
(HT)
instead
receive
cardiac
support
from
left
ventricular
assist
devices
(LVAD).
In
the
absence
other
contraindications,
patients
who
on
LVAD
can
lose
enough
weight
later
qualify
HT.
Bariatric
surgery
had
been
explored
as
approach
loss
this
patient
population
was
found
be
safe
effective
option.
One
recent
systematic
review
meta-analysis
has
shown
67.4%
able
listed
after
bariatric
subsequent
(95%CI:
0.477-0.871).
Of
these,
32.5%
would
go
transplant
0.201-0.448).
There
were
also
numerous
cases
whose
function
improved
such
that
they
delisted
HT
some
removal
their
LVAD.
many
perioperative
considerations
when
evaluating
LVADs
surgery.
However,
careful
selection
by
multidisciplinary
team
mindful
preparation,
have
opportunity
longer
years
life.
Язык: Английский